2018
Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001)
Brys M, Ellenbogen A, Fanning L, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Graham D, Weihofen A, Cedarbaum J. Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.s26.001.Peer-Reviewed Original Research
1991
Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study.
Koller WC, Block GA, Ahlskog JE, Ahrens S, Cedarbaum JM, Cyhan G, Goetz CG, LeWitt PA, Liss C, McLean L, Moses H, Muenter M, Nausieda P, Sanchez-Ramos J, Reich S, Singer C, Stellar S, Weiner W. Effect of MK-458 (HPMC) in Parkinson's Disease Previously Untreated With Dopaminergic Drugs. A Double-Blind, Placebo-Controlled Multicenter Study. Clinical Neuropharmacology 1991, 14: 322. PMID: 1913699, DOI: 10.1097/00002826-199108000-00004.Peer-Reviewed Original ResearchConceptsMK-458Early Parkinson's diseaseParkinson's diseaseDopaminergic drugsDisability Rating ScoreDopamine receptor agonismPlacebo-controlled evaluationPatient global assessmentClinical rating scalesParkinsonian symptomsAntiparkinsonian efficacyMulticenter studyAdverse reactionsIdeal treatmentReceptor agonistReceptor agonismSustained release formulationPlaceboGlobal assessmentDiseaseRating ScaleSignificant decreaseDrugsPatientsRating scores